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Abstract
Background: Thrombosis and coagulopathy are the commonest hematological manifestations of envenomation
of Russell’s viper venom (RVV). Factor X is activated by a factor X-activating enzyme from Russell’s viper venom
(RVV-X) to start the coagulation cascade. We established an animal model with local ischemic effects induced by
RVV. We tried to treat RVV envenomation with antiplatelets and anticoagulants without recourse to antivenom.
Methods: RVV was injected into the foot pad of mice. We observed the effects at different intervals and compared
local changes in ischemia with drug treatment after 30 min.
Results: A combination of aspirin plus tirofiban could prevent the ischemic change induced by RVV. The
antithrombotic effects of single-use of aspirin or tirofiban were better than single-use of heparin or clopidogrel.
Conclusion: The aspirin + tirofiban group had a better outcome with respect to prevention of tissue ischemia and
gangrene. This indicates that the activation and aggregation of platelets is the major cause of thrombosis induced
by RVV.
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Background
Daboia russelli (“Russell’s viper”) is distributed through-
out ten South-East Asian countries, including Taiwan
[1]. The effects of Russell’s viper venom (RVV) can lead
to many different severe conditions such as coagulopa-
thy, thrombotic microangiopathy [2], stroke [3], renal
failure [4], generalized increase in capillary permeability,
and rhabdomyolysis and neurotoxicity. However, these
effects can vary among the different subspecies [5, 6].
Incoagulable blood caused by consumption coagulopathy
(including disseminated intravascular coagulation (DIC)
and thrombocytopenia) is one of the commonest fea-
tures and the leading cause of death due to RVV across
the entire geographical distribution of the species [5–7].
DIC induced by RVV can lead to massive occlusion of
the renal microvasculature with fibrin deposition and
parenchymal ischemia [8] and may be a predisposing
factor of acute renal failure. Disseminated thrombus for-
mation has been shown to develop in the large vessels of
small animals bitten by Russell’s viper [7, 9]. DIC with
coagulation factors activated by an activator of factor X
from the RVV can eventually lead to the production of
stabilized fibrin, which could be the reason for vessel
obstruction [7]. Systemic thrombosis was reported in
15 % of patients with systemic envenoming from Daboia
russelli formosensis (Formosan Russell’s viper) [10]. From
our experience, the severity of DIC, renal failure, and
thrombocytopenia caused by Formosan Russell’s viper
venom is associated with clinical outcome (Wu et al. un-
published data). We wanted to create an animal model
for the hemorrhagic property of Formosan Russell’s viper
venom. Anticoagulation agents or antiplatelet agents
could then be tested to see if they could prevent venom-
induced thrombosis and sub sequent organ damage.
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Thrombosis occludes vessels, which then leads to local
tissue ischemia; the subsequent tissue necrosis is sus-
pected to be the leading cause of multiple-organ damage.
An animal model of RVV-induced thrombosis has not
been reported. We constructed an animal model with
measurement of local changes in cyanosis, gangrene,
mummification, and tissue necrosis after injection of a
sub-lethal dose of RVV into the foot pad of mice to mimic
the thrombosis caused by RVV. We then used the model
to test aspirin, clopidogrel, tirofiban and heparin for the




All snakes were obtained in eastern Taiwan. The venom of
Daboia russelli formosensis was collected directly from the
snakebite through parafilm in a test-tube every month.
Each batch of venom was pooled from a one-year collec-
tion of more than eight Formosan Russell’s vipers. We
tested the LD50 of RVV in 25-gmice via the intraperito-
neal route.
Animal model
Female NMRI mice from the National Animal Center (age,
6–8 weeks; 25 ± 3 g) were used. Aspirin, tirofiban, clopido-
grel and heparin were the anticoagulant drugs used.
Prior to anticoagulant agent injections, sub-lethal
doses of RVV (0.05 μL) were injected into the left foot
pads of each experimental mice. This dosage was chosen
because the LD50 through this inject route was demon-
strated in literature, in tested mice, to be 0.1 μL. Subse-
quently, anticoagulant agents were injected via the
intraperitoneal route 30 min after envenomation. The
degree of local ischemic change and the change in kinet-
ics at different time intervals were compared with the
drugs treated 30 min after envenomation.
Drugs
Aspirin (brand name, Stin; manufactured by China
Chemical & Pharmaceutical Company Limited, Taiwan),
tirofiban (Aggrastat; MSD, USA), clopidogrel (Plavix;
Sanofi Aventis, France) and heparin (Agglutex; China
Chemical & Pharmaceutical) were used.
Effects of aspirin
Eighteen mice were divided into three groups of six. All
mice were injected with 0.05μLvenom in the left foot pad.
Group 1 was treated once with aspirin (10 mg/kg, i.p.).
Group 2 was treated with aspirin once (40 mg/kg, i.p.).
Group 3 was the control group and had no treatment. The
observation time intervals were day-1, day-2, and day-7.
Effects of tirofiban plus another drug
Thirty mice were divided into five groups of six
mice were injected with 0.05μLvenom into their left
foot pad. Except for the control group, all other
mice were injected with tirofiban (12 mg/kg) initially
and every 8 h until the experiment was complete.
Group 1 was the control group and agents were not
administered. Mice in group 2 were injected with tir-
ofiban only. Group 3 contained mice that were add-
itionally injected once with aspirin (10 mg/kg, i.p.).
Group 4 contained mice that were additionally
injected once with clopidogrel (1 mg, i.p.). Group 5
contained mice that were additionally injected with
heparin (5 units, i.p.). The observation time interval
was 16 h and 48 h after injection.
Effects of clopidogrel and heparin
In addition to the control group, two groups of six mice
were also studied. Group 1 was administered clopidogrel
(1 mg/25 g weight, i.p.) and group 2 was given heparin
(5 units, i.p.). Changes were observed at 8, 16, and 48 h.
Results
The thrombogenic mouse foot model
The degree and kinetics of ischemia in local tissue was
constant among the six mice in each group (Tables 1
and 2). The natural course of envenoming in mice feet
is shown in Fig. 1. We observed changes in mice feet
at 15 min, 16 h, 48 h and 7 days after envenoming.
Fifteen minutes after envenoming, local tissue cyanosis
was noted. A gangrenous change in mice feet was
observed 16 h after envenoming. Mummification of
mice feet was observed after 48 h. Foot necrosis was
observed on day7 (Fig. 1). The distinction of mummifi-
cation (dry gangrene) and gangrene was made because
gangrene, when properly treated, is reversible.
Table 1 Preventative effects of antiplatelets and anticoagulants
against tissue ischemia induced by RVV
Treatment Percentage of ischemic change (%)
Cyanosis Gangrene Mummification Necrosis
Negative
(venom only)
100 % (6/6) 100 % (6/6) 100 % (6/6) 100 % (6/6)
Aspirin (As) low 100 % (6/6) 100 % (6/6) 100 % (6/6) 100 % (6/6)
Aspirin high 100 % (6/6) 100 % (6/6) 0 % (0/6) 0 % (0/6)
Tirofiban(T) 100 % (6/6) 100 % (6/6) 0 % (0/6) 0 % (0/6)
Heparin (H) 100 % (6/6) 100 % (6/6) 100 % (6/6) 100 % (6/6)
Clopidogrel (C) 100 % (6/6) 100 % (6/6) 100 % (6/6) 100 % (6/6)
Ag and C 100 % (6/6) 100 % (6/6) 0 % (0/6) 0 % (0/6)
Ag and H 100 % (6/6) 100 % (6/6) 0 % (0/6) 0 % (0/6)
Ag and As 0 % (0/6) 0 % (0/6) 0 % (0/6) 0 % (0/6)
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However tissue mummification is irreversible and will
ultimately lead to tissue necrosis.
Effects of aspirin at different doses
A high dose of aspirin (40 mg/kg) was better than a
lower dose (10 mg/kg) (Figs. 2 and 3). Aspirin showed
no obvious effects on early ischemic change in mice feet,
but prevented subsequent progression to gangrene
(Fig. 3). The lower-dose aspirin group showed gangren-
ous change 24 h after envenomation, and mummifica-
tion at day7. The higher-dose aspirin group showed
ischemic changes and gangrene at 24 h and 48 h; the
condition of foot recovered at day7, but local swelling
persisted. Overall, all mice did not completely recover,
but outcome in the treated group was better than that in
the control group at identical observation points.
Combined use of tirofiban with aspirin/clopidogrel/
heparin
The difference in outcome between the groups is shown
in Fig. 4 and Fig. 5. The best result occurred in the tiro-
fiban + aspirin group: the ischemia was completely pre-
vented. Necrosis was noted at the tip of the digits in the
tirofiban + heparin group. The tip of the digits and some
plantar necrosis was noted in the single-use tirofiban
group. Severe plantar necrosis was noted in the tirofiban
+ clopidogrel group. The outcome in all treated groups
was better than that in the control group.
Single use of clopidogrel and heparin
The clopidogrel group was slightly better than the hep-
arin group, but the single-use clopidogrel group and
single-use heparin group had virtually no effect on the
prevention of tissue necrosis and gangrene (Fig. 6 and
Fig. 7). Necrosis was noted and distal digits amputated
in the heparin group. The clopidogrel group showed
tissue necrosis, but amputation was not necessary. The
difference between the treatment group and control
group was not so clear. The tirofiban group showed a
better outcome than that in the heparin group and clo-
pidogrel group at identical observation points.
Discussion
Formosan Russell’s viper is the sixth most frequent cause
of poisonous snakebites in Taiwan [11]. As a result of
urbanization, Formosan Russell’s vipers have gradually
moved towards undeveloped regions. The time interval
between snakebite and administration of antivenom is
Table 2 Effects and distribution of tissue damage induced by
RVV envenomation reacted with treatment of antiplatelets and
anticoagulants
Treatment Degree of ischemic change
Cyanosis Gangrene Mummification Necrosis
Negative
(venom only)a
All plantar All plantar All plantar All plantar
Aspirin (As) low All plantar All plantar 3/4 plantar 1/2 plantar
Aspirin high All plantar 1/2 plantar none none
Tirofiban (T)b Half plantar Digits none none
Heparin (H) All plantar 1/2 plantar 1/2 plantar 1/2 plantar
Clopidogrel (C) All plantar 1/2 plantar 1/2 plantar 1/2 plantar
Ag and Cc All plantar 3/4 plantar none none
Ag and Hc Digits Digits none none
Ag and Asb none none none none
aReference to Fig. 1
bReference to Fig. 4
cReference to Fig. 5
Fig. 1 The natural course of venom, injected at foot of mice. a venom injected 15 min later. b venom injected 1 day later. c venom injected
2 days later. d venom injected 7 days later
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the major factor of successful treatment [12, 13]. Pa-
tients bitten by Formosan Russell’s viper (particularly in
southern and eastern Taiwan) are usually far away from
hospitals that have this antivenom, so replacing the anti-
venom with another medical treatment is crucial. Coag-
ulopathy is the major effect of RVV envenomation [3,
14]. We tested various antiplatelets and anticoagulants
to control the effect of coagulopathy to improve the out-
come of RVV envenomation.
The component RVV-X in RVV acts on factor X to
increase the amount of thrombin. An increased concen-
tration of thrombin activates platelets and enhances clot
formation. Platelet-rich clots are resistant to fibrinolysis
[15]. Antiplatelet agents may help to prevent further
activation and aggregation of platelets, and reduce the
ratio of platelets compared with other components in
clots.
Aspirin alone at a high dose showed obvious protec-
tion from venom-induced ischemia and necrosis of
tissue (Fig. 3). The effect of aspirin was dose-dependent,
but the adverse effects of high-dose aspirin are internal
bleeding and bleeding tendency, and the dose is rela-
tively high in humans. The recommended maximum
dose of aspirin for anti-inflammatory purposes is
4500 mg/day [16]. Aspirin is relatively inexpensive and
readily available in pharmacies. It has been used for de-
cades as an analgesic and for the prevention of throm-
bosis. Aspirin can be used via the oral route and is very
convenient for using outside the hospital setting. For re-
ducing aspirin dosage, we tried to combine it with other
drugs.
From the results of combined use of dual antiplatelet
agents, tirofiban + aspirin produced a better outcome
than that in the other groups (Fig. 4 and Table 1). All
mice feet fully protected without the use of antivenom.
The aspirin dose was reduced from 40 mg/kg to 10 mg/
kg, an acceptably low analgesic dose [16]. The effect of
tirofiban + heparinon outcome was moderate. However,
Fig. 2 The effects of low dose (10 mg/kg) post-envenomation Aspirin treatment at day 1, 2 and 7. a 1 day later. b 2 days later. c 7 days later
Fig. 3 The effects high dose (40 mg/kg) post-envenomation Aspirin treatment at day 1, 2 and 7. a 1 day later. b 2 days later. c 7 days later
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the recovery in mice feet was partial, and the toe tips
were necrotized, but outcome was better than in the
single-use tirofiban group. The tirofiban + clopidogrel
group showed no difference from the control group. Tir-
ofiban + aspirin could completely reverse the thrombotic
effects induced by the venom toxin of Formosan Rus-
sell’s viper without the use of antivenom.
Aspirin is well known for its antiplatelet properties, and
is used to treat ischemic stroke, angina and acute myocar-
dial infarction [17]. Aspirin irreversibly inactivates cyclo-
oxygenase and then blocks thromboxane formation [18].
Thromboxane acts as a strong signal to amplify platelet
activation by inducing irreversible platelet aggregation
[19]. Thromboxane inhibits the activity of adenyl cyclase,
leading to intraplatelet activation signals [20]. A decreased
level of thromboxane inhibits the aggregation of platelets
at injured endothelium, and blocks clot formation [21].
Heparin is used in stroke [22], acute coronary syn-
drome [23], deep-vein thrombosis [24–27], pulmonary
embolism [24–27] and in cardiopulmonary bypass due
to its anticoagulation effects. Heparin combined with an-
tithrombin then inactivates thrombin, but has no effects
on thrombin already adhered to fibrin [28]. The hep-
arin–antithrombin complex can inhibit activation of fac-
tor X with high specificity [29], but heparin has little
effect on already formed clots [30].
ADP binds to the Gq-protein-linked P2Y1 receptor on
platelets, causing a change in cell shape, calcium
mobilization, and initiation of reversible aggregation [31].
ADP also binds to the Gi-linked P2Y12 receptor on plate-
lets to amplify aggregation via adenylylcyclase-mediated
production of cyclic AMP [32]. Several studies reported
the important role of the P2Y12 receptor in platelet
thrombus formation and stabilization of collagen-coated
Fig. 4 The effects of post-envenomation treatment with tirofiban and aspirin. a One day after tirofiban treatment. b Two days after tirofiban treatment.
c One day after tirofiban + aspirin treatment. d Two days after tirofiban + aspirin treatment
Fig. 5 The effects of post-envenomation treatment with tirofiban, and clopidogrel or heparin. a One day after tirofiban + clopidogrel treatment. b
Two days after tirofiban + clopidogrel treatment. c One day after tirofiban + heparin treatment. d Two days after tirofiban + heparin treatment
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surfaces under flow conditions [33–35]. The resulting
platelet activation triggers a conformational change in
glycoprotein IIb/IIIa receptors, which increases their
affinity for fibrinogen. Clopidogrel acts on the ADP recep-
tor on the platelet surface and inhibits platelet activation
[36, 37], but has no effects on collagen-mediated activa-
tion and aggregation of platelets. We hypothesize that the
observed endothelial damages were results of the exposure
of collagen fibers to zinc metalloproteinase haemorrhagins
that are present in RVV. This hypothesis may explain the
lack of platelet inhibition by clopidogrel in this study.
Tirofiban is non-peptide small molecule that acts as an
inhibitor of the glycoprotein IIb/IIIa receptor complex on
the surface of platelets. It is used with aspirin or heparin
in the treatment of angina and non-Q myocardial infarc-
tion [23]. The surface glycoproteins of platelets can com-
bine with exposed collagen fibers in the vessel wall.
Inhibition of platelet adherence to collagen fibers can pre-
vent platelets from activation and aggregation, thereby
stopping clot formation.
Aspirin inhibits the aggregation of platelets and stabi-
lizes platelets, preventing activation then blocking clot
formation. The inhibition is irreversible until new plate-
lets are produced. Combined use of a glycoprotein IIb/
IIIa inhibitor and aspirin stabilized platelets from activa-
tion and stopped clot formation. Platelet phospholipids
Fig. 6 The effects of post-envenomation treatment with a single dose of clopidogrel. a clopidogrel (1 mg/BW 25 g) 8 h later. b clopidogrel
(1 mg/BW 25 g) 1 day later. c clopidogrel (1 mg/BW 25 g) 2 days later
Fig. 7 The effects of post-envenomation treatment with a single dose of heparin. a heparin(5U/BW 25 g) 8 h later. b heparin(5U/BW 25 g) 1 day
later. c heparin(5U/BW 25 g) 2 days later
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help to activate factor X in the intrinsic pathway, and
the formation of thrombin from prothrombin in extrin-
sic and intrinsic pathways. Platelet stabilization therefore
prevents prothrombin being formed from thrombin.
McFarlane was the first to identify activation off actor X
in RVV [38–40]. RVV-X (the factor X-activating enzyme
from RVV) has been well characterized as a proteinase
[41, 42]. Irrespective of the rapidity of treatment for
RVV envenomation, the RVV-X in venom will act as fac-
tor X before treatment to start to coagulation cascade.
RVV-X acts before heparin in almost all conditions of
envenoming, and coagulation started immediately after
envenoming, Heparin works as an anticoagulant to pre-
vent further clotting but cannot inhibit the action of
platelets, and has no effect on clotting that has already
occurred. Heparin therefore cannot reverse the effects of
RVV for tissue ischemia and gangrene. Outcome in the
aspirin plus tirofiban group with respect to prevention
of tissue ischemia and gangrene was better than that in
the heparin group. This indicated that the activation and
aggregation of platelets was the major reason for throm-
bosis induced by RVV.
Conclusion
Polyvalent antivenom is the “gold-standard” treatment
for envenomation of Formosan Russell’s viper. However,
antivenom just neutralizes the snake toxin to block the
subsequent coagulation cascade, but there is no evidence
that it affects already formed fibrin (or even thrombosis).
The reversal and prevention of toxin-induced DIC and
renal failure of antivenom is effective only if administered
early. From the present study, aspirin + tirofiban showed
an excellent outcome without the need for antivenom. We
suggest the use of aspirin plus tirofiban should be used for
envenomation by Russell’s viper irrespective of whether
specific antivenom is available or not. Antivenom is
reserved and prescribed only in specific hospitals in
Taiwan, but aspirin and tirofiban are available in most
hospitals. The accessibility of aspirin is much higher than
antivenom, particularly for mountaineers and villagers far
from such specialist hospitals. For victims of snakebites
far away from such hospitals, we tried to afford effective
and safe first-aid to prevent the adverse effects of RVV.
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